Fact CheckerSign in

NCT07064499Active, not recruiting

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes

CGM Boosted by Artificial Intelligence for Better Glycaemic Control in T2 Diabetes: a Real-life Multicentre Observational Study in Belgium.

Source: ClinicalTrials.gov · Last updated 11 Aug 2025

Brief summary (registry, in English)

Title: CGM Boosted by Artificial Intelligence for better glycaemic control in T2 Diabetes : a real-life multicenter observational study in Belgium - MAGIC-T2D Background: In Belgium, since May 2023, reimbursement for continuous glucose monitoring systems has been extended to people with type 2 diabetes taking multiple injections of insulin. Despite the results of previous studies, the impact of this technology in terms of glycaemic control and patient-reported outcomes (PROMs) in real life for patients with type 2 diabetes is still unclear. Objective: To evaluate the impact of the CGMs on glycemic control and PROMs in people living with type 2 diabetes under real-life conditions. Methods and analysis: In a multicenter real-world observational study, more than 440 people with type 2 diabetes under multiple daily injection therapy who start to be monitored by a CGM in one of the 13 participating Belgian centers, will be followed for a period of 24 months. Outcomes: The primary and secondary endpoint are respectively the evolution of time spent in range (defined as a sensor glucose value between 70 and 180 mg/dL) and HbA1c from before start to 12 months after start of the CGM. Exploratory objectives will be studied using artificial intelligence (AI) to study glucose profiles to characterize the heterogeneity of type 2 diabetes.

Status (registry)
Active, not recruiting
Study type
Observational
Enrollment
440 (estimated)
First submitted
11 Jul 2025
Start date
15 Dec 2023
Primary completion date
31 Jul 2026
Lead sponsor
Erasme University Hospital
NCT number
NCT07064499

What you commit to

  • Study type: Observational
  • Planned participants: 440
  • From 15 Dec 2023 to the primary completion date, 31 Jul 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Treatment that raises blood sugar levels (corticosteroids, etc.)

Other illness

  • Secondary and type 1 diabetes

Other

  • Dialysis
  • Patient not able to sign the Informed Consent

Who the study is looking for

  • Type 2 diabetes on MDI and starting CGM

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
HUB Hôpital Erasme
Coordinator of this site? Confirm its status
BrusselsBelgiumUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.